Mesenchymal stem cell therapy as adjunctive treatment in pediatric patients with severe acquired brain injury: a single-center retrospective case series - Scorecard - MDSpire
Advertisement
Mesenchymal stem cell therapy as adjunctive treatment in pediatric patients with severe acquired brain injury: a single-center retrospective case series
Clinical Scorecard: Adjunctive Use of Mesenchymal Stem Cell Therapy in Children with Severe Acquired Brain Injury: A Retrospective Case Series from a Single Center
At a Glance
Category
Detail
Condition
Severe acquired brain injury
Key Mechanisms
Paracrine, immunomodulatory, anti-inflammatory, and trophic effects of mesenchymal stem cells (MSCs)
Target Population
Critically ill pediatric patients with severe acquired brain injury
Care Setting
Pediatric Intensive Care Unit (PICU)
Key Highlights
Six pediatric patients received adjunctive MSC therapy.
Median Glasgow Coma Scale (GCS) improved from 4 to 11 post-therapy.
Pediatric Cerebral Performance Category (PCPC) scores decreased from 5 at baseline to 3 at 6 months.
No procedure-related adverse events were observed.
All patients survived the treatment course.
Guideline-Based Recommendations
Diagnosis
Assessment of neurological status using GCS and PCPC.
Management
Adjunctive MSC therapy in conjunction with conventional intensive care.
Monitoring & Follow-up
Follow-up neuroimaging and neurological outcomes at 1 and 6 months.
Risks
Potential for adverse events related to MSC administration, though none were observed in this study.
Patient & Prescribing Data
Pediatric patients with severe acquired brain injury, including hypoxic-ischemic and traumatic brain injuries.
MSCs administered at a dose of 1–2 × 10^6 cells/kg per session over 3–5 sessions.
Clinical Best Practices
Utilize MSC therapy as an adjunct to conventional care in severe acquired brain injury.
